vs
吉利德科学（GILD）与Targa Resources（TRGP）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是Targa Resources的2.0倍（$7.9B vs $4.1B），吉利德科学净利率更高（27.5% vs 13.4%，领先14.1%），吉利德科学同比增速更快（4.7% vs -7.9%），吉利德科学自由现金流更多（$3.1B vs $542.3M），过去两年吉利德科学的营收复合增速更高（8.9% vs 0.8%）
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
Targa Resources Corp.为财富500强企业，总部位于美国得克萨斯州休斯敦，是美国规模最大的中游能源基础设施企业之一，主营天然气及天然气凝液输送业务，运营资产主要集中在墨西哥湾沿岸，得克萨斯州与路易斯安那州为核心布局区域，马修·J·梅洛伊自2020年起担任首席执行官。
GILD vs TRGP — 直观对比
营收规模更大
GILD
是对方的2.0倍
$4.1B
营收增速更快
GILD
高出12.6%
-7.9%
净利率更高
GILD
高出14.1%
13.4%
自由现金流更多
GILD
多$2.6B
$542.3M
两年增速更快
GILD
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.9B | $4.1B |
| 净利润 | $2.2B | $545.0M |
| 毛利率 | 79.5% | 43.1% |
| 营业利润率 | 25.0% | 22.6% |
| 净利率 | 27.5% | 13.4% |
| 营收同比 | 4.7% | -7.9% |
| 净利润同比 | 22.4% | 55.3% |
| 每股收益（稀释后） | $1.75 | $2.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GILDTRGP
| Q4 25 | $7.9B | $4.1B | ||
| Q3 25 | $7.8B | $4.2B | ||
| Q2 25 | $7.1B | $4.3B | ||
| Q1 25 | $6.7B | $4.6B | ||
| Q4 24 | $7.6B | $4.4B | ||
| Q3 24 | $7.5B | $3.9B | ||
| Q2 24 | $7.0B | $3.0B | ||
| Q1 24 | $6.7B | $4.0B |
净利润GILDTRGP
| Q4 25 | $2.2B | $545.0M | ||
| Q3 25 | $3.1B | $478.4M | ||
| Q2 25 | $2.0B | $629.1M | ||
| Q1 25 | $1.3B | $270.5M | ||
| Q4 24 | $1.8B | $350.9M | ||
| Q3 24 | $1.3B | $387.4M | ||
| Q2 24 | $1.6B | $298.5M | ||
| Q1 24 | $-4.2B | $275.2M |
毛利率GILDTRGP
| Q4 25 | 79.5% | 43.1% | ||
| Q3 25 | 79.8% | 39.6% | ||
| Q2 25 | 78.8% | 42.8% | ||
| Q1 25 | 76.9% | 28.6% | ||
| Q4 24 | 79.1% | 33.7% | ||
| Q3 24 | 79.1% | 38.6% | ||
| Q2 24 | 77.8% | 27.9% | ||
| Q1 24 | 76.8% | 19.3% |
营业利润率GILDTRGP
| Q4 25 | 25.0% | 22.6% | ||
| Q3 25 | 42.8% | 20.2% | ||
| Q2 25 | 34.9% | 24.3% | ||
| Q1 25 | 33.6% | 11.9% | ||
| Q4 24 | 32.4% | 15.9% | ||
| Q3 24 | 11.8% | 18.9% | ||
| Q2 24 | 38.0% | 20.6% | ||
| Q1 24 | -64.6% | 16.0% |
净利率GILDTRGP
| Q4 25 | 27.5% | 13.4% | ||
| Q3 25 | 39.3% | 11.5% | ||
| Q2 25 | 27.7% | 14.8% | ||
| Q1 25 | 19.7% | 5.9% | ||
| Q4 24 | 23.6% | 8.0% | ||
| Q3 24 | 16.6% | 10.1% | ||
| Q2 24 | 23.2% | 9.8% | ||
| Q1 24 | -62.4% | 6.9% |
每股收益（稀释后）GILDTRGP
| Q4 25 | $1.75 | $2.51 | ||
| Q3 25 | $2.43 | $2.20 | ||
| Q2 25 | $1.56 | $2.87 | ||
| Q1 25 | $1.04 | $0.91 | ||
| Q4 24 | $1.43 | $1.44 | ||
| Q3 24 | $1.00 | $1.75 | ||
| Q2 24 | $1.29 | $1.33 | ||
| Q1 24 | $-3.34 | $1.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $166.1M |
| 总债务越低越好 | $24.9B | $16.7B |
| 股东权益账面价值 | $22.7B | $3.1B |
| 总资产 | $59.0B | $25.2B |
| 负债/权益比越低杠杆越低 | 1.10× | 5.43× |
8季度趋势，按日历期对齐
现金及短期投资GILDTRGP
| Q4 25 | $68.0M | $166.1M | ||
| Q3 25 | $19.0M | $124.1M | ||
| Q2 25 | $69.0M | $113.1M | ||
| Q1 25 | — | $151.4M | ||
| Q4 24 | — | $157.3M | ||
| Q3 24 | — | $127.2M | ||
| Q2 24 | — | $166.4M | ||
| Q1 24 | — | $109.9M |
总债务GILDTRGP
| Q4 25 | $24.9B | $16.7B | ||
| Q3 25 | $24.9B | $16.7B | ||
| Q2 25 | $24.9B | $16.1B | ||
| Q1 25 | $25.0B | $15.5B | ||
| Q4 24 | $26.7B | $13.8B | ||
| Q3 24 | $23.2B | $13.6B | ||
| Q2 24 | $23.3B | $13.0B | ||
| Q1 24 | $25.2B | $12.5B |
股东权益GILDTRGP
| Q4 25 | $22.7B | $3.1B | ||
| Q3 25 | $21.5B | $2.7B | ||
| Q2 25 | $19.7B | $2.6B | ||
| Q1 25 | $19.2B | $2.5B | ||
| Q4 24 | $19.3B | $2.6B | ||
| Q3 24 | $18.5B | $2.6B | ||
| Q2 24 | $18.3B | $2.5B | ||
| Q1 24 | $17.5B | $2.7B |
总资产GILDTRGP
| Q4 25 | $59.0B | $25.2B | ||
| Q3 25 | $58.5B | $24.2B | ||
| Q2 25 | $55.7B | $23.5B | ||
| Q1 25 | $56.4B | $22.8B | ||
| Q4 24 | $59.0B | $22.7B | ||
| Q3 24 | $54.5B | $21.9B | ||
| Q2 24 | $53.6B | $21.3B | ||
| Q1 24 | $56.3B | $20.8B |
负债/权益比GILDTRGP
| Q4 25 | 1.10× | 5.43× | ||
| Q3 25 | 1.16× | 6.19× | ||
| Q2 25 | 1.27× | 6.21× | ||
| Q1 25 | 1.30× | 6.34× | ||
| Q4 24 | 1.38× | 5.32× | ||
| Q3 24 | 1.26× | 5.28× | ||
| Q2 24 | 1.28× | 5.25× | ||
| Q1 24 | 1.44× | 4.63× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $1.5B |
| 自由现金流经营现金流 - 资本支出 | $3.1B | $542.3M |
| 自由现金流率自由现金流/营收 | 39.4% | 13.4% |
| 资本支出强度资本支出/营收 | 2.6% | 23.8% |
| 现金转化率经营现金流/净利润 | 1.52× | 2.76× |
| 过去12个月自由现金流最近4个季度 | $9.5B | $584.1M |
8季度趋势，按日历期对齐
经营现金流GILDTRGP
| Q4 25 | $3.3B | $1.5B | ||
| Q3 25 | $4.1B | $599.2M | ||
| Q2 25 | $827.0M | $858.3M | ||
| Q1 25 | $1.8B | $954.4M | ||
| Q4 24 | $3.0B | $1.3B | ||
| Q3 24 | $4.3B | $540.9M | ||
| Q2 24 | $1.3B | $904.5M | ||
| Q1 24 | $2.2B | $876.4M |
自由现金流GILDTRGP
| Q4 25 | $3.1B | $542.3M | ||
| Q3 25 | $4.0B | $-72.6M | ||
| Q2 25 | $720.0M | $-47.8M | ||
| Q1 25 | $1.7B | $162.2M | ||
| Q4 24 | $2.8B | $601.0M | ||
| Q3 24 | $4.2B | $-287.9M | ||
| Q2 24 | $1.2B | $164.2M | ||
| Q1 24 | $2.1B | $206.6M |
自由现金流率GILDTRGP
| Q4 25 | 39.4% | 13.4% | ||
| Q3 25 | 51.0% | -1.7% | ||
| Q2 25 | 10.2% | -1.1% | ||
| Q1 25 | 24.8% | 3.6% | ||
| Q4 24 | 37.4% | 13.6% | ||
| Q3 24 | 55.2% | -7.5% | ||
| Q2 24 | 17.2% | 5.4% | ||
| Q1 24 | 31.6% | 5.2% |
资本支出强度GILDTRGP
| Q4 25 | 2.6% | 23.8% | ||
| Q3 25 | 1.9% | 16.2% | ||
| Q2 25 | 1.5% | 21.3% | ||
| Q1 25 | 1.6% | 17.4% | ||
| Q4 24 | 1.9% | 16.5% | ||
| Q3 24 | 1.9% | 21.5% | ||
| Q2 24 | 1.9% | 24.3% | ||
| Q1 24 | 1.6% | 16.8% |
现金转化率GILDTRGP
| Q4 25 | 1.52× | 2.76× | ||
| Q3 25 | 1.35× | 1.25× | ||
| Q2 25 | 0.42× | 1.36× | ||
| Q1 25 | 1.34× | 3.53× | ||
| Q4 24 | 1.67× | 3.78× | ||
| Q3 24 | 3.44× | 1.40× | ||
| Q2 24 | 0.82× | 3.03× | ||
| Q1 24 | — | 3.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
TRGP
| Logistics And Transportation | $3.4B | 83% |
| Natural Gas Reserves | $393.1M | 10% |
| Storage Terminaling And Export | $130.9M | 3% |
| Oil And Condensate | $112.0M | 3% |
| NGL Transportation Fractionation And Services | $64.7M | 2% |
